Skip to main content
. 2018 Aug 31;9(68):32885–32899. doi: 10.18632/oncotarget.25972

Figure 2. ATO synergizes with FLT3 TKIs to reduce proliferation and clonogenicity of FLT3/ITD+ cell lines.

Figure 2

A. Cells were treated with sorafenib (0-16nM) or quizartinib (0-8nM) either alone or in combination with ATO (0-4μM) for 24 hours. Cell proliferation was measured in quadruplicate by MTT assay. B. CFU counts at 9 and 14 days of Molm14 and MV4;11 cells cultured in methylcellulose-based medium (Stemcell Technologies, H4230) treated with sorafenib (4nM) and/or ATO (1μM). Data indicate average ± SD. N=3. Representative images of colonies are shown below. Images were acquired at room temperature using a Nikon Eclipse Ti-E inverted microscope imaging system with a Nikon NIS-Elements AR3.0 software.